3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Launched by BARBARA ANN KARMANOS CANCER INSTITUTE · Jul 7, 2009

Keywords

ClinConnect Summary

This clinical trial is studying a special type of imaging called 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging in patients who have various types of cancer, including brain tumors, leukemia, lymphoma, and other blood cancers. The goal of this study is to see if this imaging can help doctors find and diagnose cancer more accurately. It may also help them understand how well a patient might respond to treatment and assist in planning the best treatment options.

To be eligible for this trial, participants need to have a confirmed cancer diagnosis or be awaiting a biopsy or surgery for a suspected cancer. They should be able to stay still during the imaging process. Patients who are pregnant or nursing cannot participate, and those who can become pregnant must use effective birth control during the study. If you join the trial, you can expect to undergo FLT PET imaging, which is a non-invasive procedure that helps gather important information about your cancer. The trial is currently recruiting participants, and all genders and adults aged 18 and older are welcome to apply.

Gender

ALL

Eligibility criteria

• DISEASE CHARACTERISTICS:
• * Meets one of the following criteria:
• • Histologically confirmed solid tumor or hematologic malignancy
• • Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
• PATIENT CHARACTERISTICS:
• • Able to lie still in the PET scanner
• • Girth and weight must be suitable to enter the gantry
• • Not pregnant or nursing
• • Negative pregnancy test
• • Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• • Not specified